JP2024521398A5 - - Google Patents
Info
- Publication number
- JP2024521398A5 JP2024521398A5 JP2023575695A JP2023575695A JP2024521398A5 JP 2024521398 A5 JP2024521398 A5 JP 2024521398A5 JP 2023575695 A JP2023575695 A JP 2023575695A JP 2023575695 A JP2023575695 A JP 2023575695A JP 2024521398 A5 JP2024521398 A5 JP 2024521398A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21178712.2 | 2021-06-10 | ||
| EP21178712 | 2021-06-10 | ||
| PCT/EP2022/065826 WO2022258805A1 (en) | 2021-06-10 | 2022-06-10 | Treatment of obesity and obesity-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024521398A JP2024521398A (ja) | 2024-05-31 |
| JPWO2022258805A5 JPWO2022258805A5 (https=) | 2025-07-28 |
| JP2024521398A5 true JP2024521398A5 (https=) | 2025-07-28 |
Family
ID=76502668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575695A Pending JP2024521398A (ja) | 2021-06-10 | 2022-06-10 | 肥満及び肥満関連障害の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277813A1 (https=) |
| EP (1) | EP4351630A1 (https=) |
| JP (1) | JP2024521398A (https=) |
| KR (1) | KR20240021212A (https=) |
| CN (1) | CN117881415A (https=) |
| AU (1) | AU2022289247A1 (https=) |
| BR (1) | BR112023024968A2 (https=) |
| CA (1) | CA3221661A1 (https=) |
| IL (1) | IL309128A (https=) |
| MX (1) | MX2023014740A (https=) |
| WO (1) | WO2022258805A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| KR20250095833A (ko) * | 2023-12-19 | 2025-06-27 | 한미약품 주식회사 | 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2026046202A1 (zh) * | 2024-08-26 | 2026-03-05 | 博瑞生物医药（苏州）股份有限公司 | Glp-1/gip肽或含有其的药物组合物的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0606992A2 (pt) * | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN121449721A (zh) * | 2018-12-03 | 2026-02-03 | 安泰博医药 | 经修饰的gip肽类似物 |
| CA3157387A1 (en) * | 2019-12-03 | 2021-06-10 | Mette Marie Rosenkilde | Optimized gip peptide analogues |
-
2022
- 2022-06-10 KR KR1020247000556A patent/KR20240021212A/ko active Pending
- 2022-06-10 IL IL309128A patent/IL309128A/en unknown
- 2022-06-10 CN CN202280040922.8A patent/CN117881415A/zh active Pending
- 2022-06-10 MX MX2023014740A patent/MX2023014740A/es unknown
- 2022-06-10 WO PCT/EP2022/065826 patent/WO2022258805A1/en not_active Ceased
- 2022-06-10 AU AU2022289247A patent/AU2022289247A1/en active Pending
- 2022-06-10 JP JP2023575695A patent/JP2024521398A/ja active Pending
- 2022-06-10 BR BR112023024968A patent/BR112023024968A2/pt unknown
- 2022-06-10 EP EP22733387.9A patent/EP4351630A1/en active Pending
- 2022-06-10 CA CA3221661A patent/CA3221661A1/en active Pending
- 2022-06-10 US US18/565,984 patent/US20240277813A1/en active Pending